BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 23828385)

  • 21. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
    Rosen G
    Cancer Treat Res; 1993; 62():49-54. PubMed ID: 8096759
    [No Abstract]   [Full Text] [Related]  

  • 22. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Organ-preserving interventions in combined therapy of children and adolescents with osteosarcoma].
    Punanov IuA; Gafton GI; Gudz' IuV; Nabokov VV; Ivanova TV; Safonova SA; Levchenko EV; Kupatadze DD; Novik VI; Lazareva IuR; Krzhivitskiĭ PI; Petrov VG
    Vopr Onkol; 2012; 58(2):275-81. PubMed ID: 22774537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Yu W; Tang L; Lin F; Yao Y; Shen Z
    Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
    Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M
    Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
    Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
    Cohen IJ
    Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
    Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
    Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limb-sparing in patients with non-metastatic high-grade osteosarcoma.
    Samardziski M; Zafiroski G; Tolevska C; Zafirova-Ivanovska B; Kostadinova-Kunovska S; Kalicanin-Markovska M
    J BUON; 2009; 14(1):63-9. PubMed ID: 19373949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs.
    Fuchs N; Bielack SS; Epler D; Bieling P; Delling G; Körholz D; Graf N; Heise U; Jürgens H; Kotz R; Salzer-Kuntschik M; Weinel P; Werner M; Winkler K
    Ann Oncol; 1998 Aug; 9(8):893-9. PubMed ID: 9789613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
    Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
    J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma.
    Longhi A; Pignotti E; Versari M; Asta S; Bacci G
    Oncol Rep; 2003; 10(1):151-5. PubMed ID: 12469162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
    Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
    Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).
    Winkler K; Bielack S; Delling G; Salzer-Kuntschik M; Kotz R; Greenshaw C; Jürgens H; Ritter J; Kusnierz-Glaz C; Erttmann R
    Cancer; 1990 Oct; 66(8):1703-10. PubMed ID: 2208024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
    Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
    Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
    J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.